Introduction {#Sec1}
============

Clinical evidence indicates that intensive insulin therapy reduces the risk of long-term complications in patients with type 1 diabetes mellitus (T1DM) \[[@CR1]\]. However, such therapy is associated with increased risk of hypoglycemia and unawareness of hypoglycemia, in part through the modification of glucose-sensing neurons \[[@CR2], [@CR3]\]. Previous studies indicated that low hemoglobin A1c (HbA1c) and short-term variations in blood glucose are independent risk factors for hypoglycemia \[[@CR4], [@CR5]\]. However, lack of awareness of occasional episodes of hypoglycemia, such as nocturnal hypoglycemia, is not uncommon, especially in the absence of clinical signs and symptoms \[[@CR6]\]. Continuous glucose monitoring (CGM) is particularly useful to identify episodes of hypoglycemia and variability in glycemic level including episodes of both hypo- and hyperglycemia \[[@CR7]\]. The normal ranges of glycemic variability (GV) recoded by CGM have been published for normal subjects \[[@CR8]\] and patients with T1DM \[[@CR9]\].

Insulin analogue degludec (IDeg) is a formulated insulin analogue of di-hexamers that is reorganized into multi-hexamer compounds at the site of subcutaneous tissue injection \[[@CR10]\], and later degraded to monomers at a slow rate followed by absorption into the systemic circulation \[[@CR10]\]. On the basis of our clinical experience, patients with T1DM tend to avoid the use of a single dose of another insulin analogue glargine (IGlar) before breakfast with multiple bolus injections, one for each meal, because of fear of possible insufficient action of IGlar until the next morning. To our knowledge, there are no randomized crossover designed clinical trials that have compared glycemic control in T1DM under treatment with long-acting IDeg and IGlar injection "before breakfast".

Hypoglycemia and fear of hypoglycemia are some of the major concerns among patients, limiting their quality of life (QOL) and their ability to achieve glycemic targets \[[@CR11]--[@CR13]\]. The objective of this study was to compare the effects of IDeg and IGlar, in the context of GV measured by CGM, including total time spent in hypoglycemia and mean glycemic level. In addition, we used the Diabetes Therapy-Related Quality of Life Questionnaire to assess the duration of hypoglycemia and GV associated with the two insulin analogues, as well as the extent of satisfaction with each treatment \[[@CR14]\].

Methods {#Sec2}
=======

Study Subjects {#Sec3}
--------------

This study was conducted in accordance with the International Conference on Harmonization Guidelines for Good Clinical Practice and the Declaration of Helsinki \[[@CR15]\]. The study was approved by Toho University ethics committee. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. Informed consent was obtained from all patients for being included in the study.

This randomized, open-label, crossover study was conducted to determine the effects of IDeg and IGlar treatment once daily in the morning in lowering fasting blood glucose (FBG) and the severity of potential hypoglycemia (Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}). Patients were randomized to receive either IDeg or IGlar, employing identical adjustment algorithms. In the latter approach, the data from the first arm of the study were combined with those of the second arm, at the end of the study. The protocol for this trial and supporting CONSORT checklist are available as supporting information; see Checklist S1 and Protocol S1 (original language) and S2 (English translation). Recruitment took place between 2013 and 2014 and patients were followed up until December 2014. On the basis of a pilot CGM conducted in 2013 by the Toho University, Tokyo, a minimum difference in CGM parameters between the IDeg and IGlar arms over a month was expected. To achieve a power of 80%, and with a significance level of 5% (*α* = 0.05), a minimum of 10 participants in each arm with a crossover design was required (total *n* = 20 to calculate). Eligible patients were aged 20 years or older with history of T1DM for at least 1 year. The exclusion criteria included pregnant women, history or presence of active cancer or cardiovascular disease, stroke, blood pressure beyond the normal range (systolic greater than 180 mmHg; diastolic greater than 100 mmHg), proliferative retinopathy or macroangiopathy or active infectious disease such as hepatitis B and C infections.Fig. 1Enrollment of participants in the study Fig. 2Study design. *IAsp* insulin aspart, *IDeg* insulin degludec, *IGlar* insulin glargine

Patients were also excluded if they had ever been diagnosed with type 2 diabetes, had hemoglobin less than 11 g/dL, platelet count less than 10 × 10^9^/L, fasting triglycerides greater than 500 mg/dL (greater than 5.7 mmol/L), liver disease, alanine aminotransferase (ALT), or aspartate aminotransferase (AST) level of more than 2.5-fold the upper limit of normal, renal transplantation or serum creatinine greater than 2.0 mg/dL (greater than 177 mmol/L), more than two episode of severe hypoglycemia within the preceding 12 months or diagnosis of hypoglycemia unawareness, participation in a weight loss program, or at least two emergency room visits or hospitalization for poor glucose control within the preceding 6 months.

At baseline (before study entry), all 20 patients were treated during the prestudy period (12 weeks) with insulin aspart (IAsp) and basal insulin. IAsp was later continued at a dose of insulin titration algorithms, as stated below, throughout the 24-week duration of the study (Fig. [2](#Fig2){ref-type="fig"}). The study included 20 participants who were randomized by computer-generated assignment to receive first either IDeg (*n* = 10) or IGla (*n* = 10) continuously for 12 weeks. CGM was performed in a blinded fashion on three consecutive days (72--84 h) of the last week of the 12-week study period (Fig. [1](#Fig1){ref-type="fig"}). CGM is able to record glucose values for 5 days; however, to complete 24-h recording sets, we used 3 days in the middle. Then basal insulin was switched from IDeg to IGla and vice versa from IGla to IDeg and treatment was continued for another 12 weeks. Again, CGM was performed in the same way as the first arm of the study. A Medtronic Diabetes (Northridge, CA) CGMS Gold continuous glucose recorder was used.

Outcome Measures and Measurements {#Sec4}
---------------------------------

To evaluate the incidence of hypoglycemia during treatment with IDeg and IGlar, we measured GV using CGM in T1DM patients. Hypoglycemia was defined as CGM of less than 70 mg/dL (less than 3.9 mmol/L). The time spent in hypoglycemia at interstitial glucose (IG) value of less than 70 mg/dL (less than 3.9 mmol/L) per 24-h period was expressed as total hypoglycemia time (%). The nocturnal period for the CGM assessment represented the time between 2400 and 0600 hours, and the time spent at IG value of less than 70 mg/dL was described as nocturnal hypoglycemia (%). The percentage of time spent with IG value between 80 and 140 mg/dL (4.4--7.8 mmol/L) was expressed as percentage of time spent at optimum glucose (%). Between- and within-day glucose SD during the nocturnal period and the daytime period (0600--2400 hours) was calculated to assess the within-patient GV. The term "between-day variability" as used here and previously \[[@CR16]\] corresponds to the previously designated term of "standard deviation between daily means" \[[@CR17]\]. The mean amplitude of glycemic excursions (MAGE) was calculated from the CGM taking into account the glycemic peaks and nadirs recorded during the 24 h beyond the average glucose values \[[@CR18]\]. The J-index was calculated using the glycemic average and SD and used to describe GV \[[@CR19]\]. On the basis of the time required to achieve steady-state circulating IDeg and previous studies on IGlar \[[@CR20]\], all basal insulin were restricted not to increase the dose before the time-to-onset, which need the 3-day interval.

The target fasting and postprandial blood glucose levels used to optimize the dose of insulin were 80--110 mg/dL (4.5--6.1 mmol/L) and 80--140 mg/dL (4.5--7.8 mmol/L), respectively. The insulin algorithm, adapted from previous studies \[[@CR16], [@CR20]\], was based on the mean fasting blood glucose of three consecutive mornings before the visit: for a mean FBG of 110--130 mg/dL (6.1--7.2 mmol/L), 131--160 mg/dL (7.3--8.9 mmol/L), and for greater than 161 mg/dL (greater than 9.0 mmol/L), the IDeg and IGlar doses were increased by 2, 3, and 4 IU, respectively. Bolus insulin titration was adopted over three consecutive days: for mean 2-h postprandial blood glucose value of 140--180 mg/dL (7.8--10 mmol/L), 181--220 mg/dL (10.1--12.2 mmol/L), and for greater than 220 mg/dL (greater than 12.2 mmol/L), the bolus insulin dose was increased by 2, 3, and 4 IU, respectively.

The dose was reduced by 2 IU in patients taking either IDeg or IGlar who experienced at least two or more hypoglycemic episodes with blood glucose values of less than 80 mg/dL (less than 4.4 mmol/L).

Treatment satisfaction was assessed at the end of each treatment period using the Diabetes Therapy-Related Quality of Life Questionnaire (DTR-QOL) \[[@CR14]\].

Statistical Analysis {#Sec5}
--------------------

All analyses were performed using the SAS (SAS Institute, Cary, NC, USA) with the intent-to-treat principle based on all patients who were randomized and took at least one dose of the study drug. All tests performed were two-sided at a prespecified a level of 0.1, and the corresponding 90% CIs were calculated. No adjustments for multiplicity were performed. The mean duration (in minutes) of individual hypoglycemic episodes according to treatment type and duration (12 weeks) was summarized and compared between the treatment periods using the Student*t* test. A *P* value less than 0.05 denoted the presence of a significant difference.

Results {#Sec6}
=======

Subject Characteristics {#Sec7}
-----------------------

The clinical characteristics of the two groups are presented in Table [1](#Tab1){ref-type="table"}. Age, duration of diabetes (years), body mass index (BMI), HbA1c (%), total daily dose of insulin (TDD) (IU/kg/day), and basal insulin percentage of TDD were similar in the two groups.Table 1Characteristics of patients of the IDeg--IGlar and IGlar--IDeg groups at baselineTotalIDeg--IGlarIGlar--IDeg*p* value*n* (male/female)20 (11/9)10 (5/5)10 (6/4)Age (years)54 ± 1655 ± 1453 ± 180.383Diabetes (years)15.2 ± 8.514.4 ± 8.616.1 ± 8.70.333Body weight (kg)62.0 ± 11.164.0 ± 10.460.0 ± 12.00.218BMI (kg/m^2^)23.7 ± 4.324.4 ± 4.423.1 ± 4.10.256HbA1c (%)7.4 ± 0.87.1 ± 0.97.7 ± 0.60.077Total daily dose of insulin (U/kg)0.68 ± 0.270.64 ± 0.230.72 ± 0.320.239Basal insulin percentage of TDD (%)41.4 ± 18.247.4 ± 21.234.9 ± 16.10.689Data are mean ± SD*TDD* mean total daily dose in IU/kg/day

Glycemic Control {#Sec8}
----------------

As shown in Table [2](#Tab2){ref-type="table"}, the average HbA1c (%), body weight (kg), BMI, TDD, and basal insulin percentage of TDD were not significantly different at each 12-week endpoint of the treatment periods. Within each 12-week study period, the mean total daily dose of insulin (IU/kg/day) and percentage of basal insulin to the TDD (%) were similar in both treatment periods. Table [3](#Tab3){ref-type="table"} shows the 24-h CGM data expressed as the mean glucose value (mg/dL), which was identical in both treatment periods (*p* = 0.435). The time spent at optimum glucose (%) representing the IG between 70 and 140 mg/dL (3.9--7.8 mmol/L) was similar in the two treatment periods (*p* = 0.434). The percentage of time in hypoglycemia per 24 h and nocturnal hypoglycemia (%) were not different between the two treatment periods (*p* = 0.300, *p* = 0.325). MAGE and J-Index were also identical in the two periods (*p* = 0.355, *p* = 0.444). Table [3](#Tab3){ref-type="table"} also shows fasting IG and day-to-day variation in fasting IG. While the mean fasting IG was similar in the two insulin treatment periods (*p* = 0.102), the magnitude of day-to-day variation in fasting IG variability was significantly higher in the IGlar treatment period than the IDeg period (*p* = 0.037). Figure [3](#Fig3){ref-type="fig"} provides a schematic representation of the CGM findings.Table 2Measures of mean body weight, body mass index, HbA1c, and dose of insulin at 12 weeks post-treatment with IDeg and IGlar periodsTotalIDegIGlar*p* value*n*402020Body weight (kg)61.7 ± 12.761.5 ± 12.561.9 ± 12.90.945BMI (kg/m^2^)23.6 ± 4.623.5 ± 4.723.6 ± 4.60.884HbA1c (%)7.2 ± 0.97.2 ± 0.87.3 ± 0.90.733Total daily dose of insulin (U/kg)0.64 ± 0.20.62 ± 0.210.65 ± 0.20.916Basal insulin percentage of TDD (%)42.3 ± 16.342.5 ± 16.942.1 ± 15.70.755Data are mean ± SD of the same insulin treatment group at 12 weeks post-treatment Table 3Results of CGM analysis at 12 weeks after treatment with IDeg and IGlarIDegIGlar*p* valueNumber of CGM records2020Mean glucose value (mg/dL)140.1 ± 40.5143.2 ± 28.40.435Optimum glucose value, 70--140 mg/dL (%)50.5 ± 21.249.3 ± 18.80.434Total hypoglycemia (%)6.6 ± 9.25.4 ± 6.50.300Nocturnal hypoglycemia (%)39.6 ± 30.635.1 ± 25.30.325Mean amplitude of glycemic excursions (MAGE)159.7 ± 65.6168.5 ± 57.70.355J-index41.2 ± 24.542.3 ± 18.10.444Mean fasting interstitial glucose (mg/dL)117.7 ± 44.4137.1 ± 30.50.102Day-to-day variation of fasting interstitial glucose (mg/dL)25.9 ± 22.043.8 ± 30.10.037Data are mean ± SD Fig. 3Schematic representation of the CGM findings. \**p* \< 0.05

Diabetes Quality of Life {#Sec9}
------------------------

We measured the total and four-subdomain scores of the original DTR-QOL (Fig. [4](#Fig4){ref-type="fig"}). While the scores of the total and subdomain of DTR-QOL (for item "burden on social activities and daily activities", "anxiety and dissatisfaction with treatment", and "hypoglycemia") were not different between the treatments, the scores of "satisfaction with treatment" subdomain improved significantly during treatment with IDeg (*p* \< 0.009).Fig. 4Comparison of total and subdomain scores of DTR-QOL between IDeg and IGlar groups (20 DTR-QOL records for each treatment period). Data are mean ± SD. Higher scores indicate better quality of life

Discussion {#Sec10}
==========

The main purpose of the present study was to evaluate the effects of morning injection of two long-acting insulin analogues, IDeg and IGlar, on the severity of hypoglycemia and GV using CGM in patients with T1DM. A recent study using CGM suggested that patients with successfully treated T1DM (i.e., HbA1c less than 7.0%) spent more than 90 min/day at blood glucose level below 70 mg/dL \[[@CR21]\]. Although no severe hypoglycemia was observed in the present study, the percentage of time spent in hypoglycemia per 24 h was similar under both IDeg and IGlar. Our results, however, showed a higher percentage of time in nocturnal hypoglycemia (between 2400 and 0600 hours; nearly 30% of the time spent in IG less than 70 mg/dL, less than 3.9 mmol/L) under both basal insulin arms, compared with that of a previous study \[[@CR21]\]. The different results were probably related to the study design; we applied strict blood glucose titration, allowing with fasting self-monitoring of blood glucose (SMBG) values between 80 and 110 mg/dL (4.4--6.1 mmol/L). Using similar safety endpoints, including hypoglycemia (which was defined as SMBG values of 101--120 mg/dL or 5.5--6.7 mmol/L), Bergenstal et al. \[[@CR22]\] demonstrated previously that LY2605541 (peglispro) improved fasting blood glucose values, with a time spent at hypoglycemia of 11% only, compared with 38% under insulin glargine. Thus, the caveats of insulin titration algorithm used in clinical trials could potentially pose serious hypoglycemia risk.

Currently, there is no gold standard for evaluation of GV. Indeed, assessment of GV in routine clinical practice remains a challenge at present. Especially in patients with T1DM, the achievement of tight glycemic control with limited intraday variability in blood glucose level remains a challenge. However, the values of mean glucose level, optimum glucose level, MAGE, J-Index, and fasting interstitial glucose in this study were similar between the two treatment periods. Thus, IDeg and IGlar both tended to improve day-to-day variation in fasting interstitial GV. In this regard, Heise et al. \[[@CR23]\] reported that the day-to-day variability was smaller in patients on IDeg compared to those on IGlar under steady-state conditions. The difference could be due to the longer duration of action and lower peak-to-trough ratio of IDeg than IGlar \[[@CR24]\]. Further studies are needed to evaluate the therapeutic application of IDeg.

In the present study, we used the Japanese version of the DTR-QOL questionnaire for Japanese patients with T1DM. This version has been validated previously \[[@CR14]\]. The total DTR-QOL score was comparable in the two insulin arms. The score for the component "satisfaction with treatment" was significantly higher in the IDeg treatment period. Our results showed that the T1DM treatment-related DTR-QOL questionnaire may help in clinical decision-making regarding the selection of the most appropriate type of insulin for patients with T1DM. Physicians should pay attention to treatment-related QOL especially in patients on insulin therapy because poor GV may result in inadequate satisfaction with the treatment.

Our study has certain limitations. First, our randomized crossover study was open-labeled, which carries concerns regarding drug-specific bias. Second, the percentage time and severity of hypoglycemia were monitored only over a relatively short period of time. Third, to some extent the A1c difference between both groups at baseline was substantial and the results could have been affected by the large SD and small number of study participants. The results need to be confirmed in long-term prospective studies of large numbers of patients.

Conclusions {#Sec11}
===========

Compared to IGla, morning injection of long-acting insulin IDeg seems to be associated with lower risk of day-to-day variation in fasting interstitial GV, as well as higher satisfaction with treatment in patients with T1DM.
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